2014
Thymic carcinoma outcomes and prognosis: Results of an international analysis
Ahmad U, Yao X, Detterbeck F, Huang J, Antonicelli A, Filosso PL, Ruffini E, Travis W, Jones DR, Zhan Y, Lucchi M, Rimner A. Thymic carcinoma outcomes and prognosis: Results of an international analysis. Journal Of Thoracic And Cardiovascular Surgery 2014, 149: 95-101.e2. PMID: 25524678, DOI: 10.1016/j.jtcvs.2014.09.124.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedChemotherapy, AdjuvantDisease-Free SurvivalFemaleHumansMaleMiddle AgedMultivariate AnalysisNeoadjuvant TherapyNeoplasm Recurrence, LocalNeoplasm StagingPractice Patterns, Physicians'Proportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesRisk FactorsSex FactorsThymectomyThymomaThyroid NeoplasmsTime FactorsTreatment OutcomeConceptsRecurrence-free survivalEarly Masaoka stageR0 resectionOverall survivalRadiation therapyMasaoka stageThymic carcinomaMale genderLonger recurrence-free survivalMedian overall survivalStage IV diseaseAdjuvant radiation therapyMasaoka stage IPreoperative radiation therapyPrimary outcome measureSquamous cell carcinomaPredominant histologic subtypeAdjuvant chemotherapyImproved OSInduction chemotherapyProlonged OSCumulative incidenceHistologic subtypeMultivariable analysisTreatment patterns
2004
Induction and Concurrent Chemotherapy With High-Dose Thoracic Conformal Radiation Therapy in Unresectable Stage IIIA and IIIB Non–Small-Cell Lung Cancer: A Dose-Escalation Phase I Trial
Socinski MA, Morris DE, Halle JS, Moore DT, Hensing TA, Limentani SA, Fraser R, Tynan M, Mears A, Rivera MP, Detterbeck FC, Rosenman JG. Induction and Concurrent Chemotherapy With High-Dose Thoracic Conformal Radiation Therapy in Unresectable Stage IIIA and IIIB Non–Small-Cell Lung Cancer: A Dose-Escalation Phase I Trial. Journal Of Clinical Oncology 2004, 22: 4341-4350. PMID: 15514375, DOI: 10.1200/jco.2004.03.022.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsArea Under CurveCamptothecinCarboplatinCarcinoma, Non-Small-Cell LungCombined Modality TherapyFemaleHumansIrinotecanLung NeoplasmsMaleMiddle AgedNeoplasm StagingPaclitaxelRadiotherapy, ConformalRemission InductionSurvival AnalysisTreatment OutcomeConceptsStage III NSCLC patientsCell lung cancerClinical target volumeConcurrent chemotherapyConformal radiation therapyNSCLC patientsPerformance statusLung cancerRadiation therapyDose-escalation phase I trialTarget volumeConventional radiotherapy dosesUnresectable stage IIIAGood performance statusLocal control rateMaximum-tolerated doseDose-limiting toxicityPhase I trialMedian survival timeOverall response rateInitial clinical target volumeInduction chemotherapyFatal hemoptysisLate toxicityStage IIIA